Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis.
- Author:
Yan HUANG
1
;
Yan-li NIE
;
Ming-ming ZHANG
;
Yu-lin LI
;
Jian-rong CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; therapeutic use; Colorectal Neoplasms; drug therapy; Fluorouracil; therapeutic use; Humans; Randomized Controlled Trials as Topic; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2012;15(4):377-381
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the benefit and safety of fluorouracil implants on colorectal cancer.
METHODSBased on the methods of Cochrane systematic reviews, databases including CBM(1982 to March 2011), CNKI(1911 to March 2011), EMBASE(1966 to March 2011), and Medline(1950 to March 2011) were searched to identify randomized controlled trials assessing the benefit of fluorouracil implants on colorectal cancer. The quality of the included studies was assessed using the Cochrane's tool for assessing bias. RevMan5.0 was used for meta-analysis.
RESULTSSixteen studies were included(n=1223). The quality of included studies was moderate. Fluorouracil implants could reduce the 2-year mortality(RR=0.33. 95% CI:0.18-0.59), 2-year metastasis rate(RR=0.35, 95% CI: 0.19-0.66), and 2-year recurrence rate(RR=0.48, 95% CI:0.36-0.65). There were no significant differences in complications and adverse effects between fluorouracil implants and the control group.
CONCLUSIONSCurrent evidence demonstrates that fluorouracil implants may modestly improve the outcome of colorectal cancer patients without increasing its adverse events. However, the results should be interpreted with caution due to the risk of bias of included studies.
